

14. The method of Claim 11, wherein said chimeric anti-CD20 antibody is produced by a transfectoma which has been deposited in TCAE8, ATCC deposit number 69119.

C  
Cmt  
15. The method of Claim 14, wherein the at least one chemotherapeutic agent is selected from the group consisting of cyclophosphamide, doxorubicin, vincristine, and prednisone.--

IN THE ABSTRACT:

Cancel the current Abstract and substitute the following therefor:

C  
C2  
--A method of treating B-cell lymphoma using a chimeric anti-CD20 antibody that provides for substantially total peripheral B-cell depletion at a dosage ranging from about 0.4 to 20 mg/kg body weight within about 24 hours post-administration, and a chemotherapeutic agent is provided.--